Boris Klimovich

Otfried Müller Str. 10
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Author Correction: Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.

Author Correction: Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.

Journal: The EMBO journal

Published: February 19, 2026

CLEC12A-directed immunocytokine with target cell-restricted IL-15 activity for treatment of acute myeloid leukemia.

CLEC12A-directed immunocytokine with target cell-restricted IL-15 activity for treatment of acute myeloid leukemia.

Journal: Frontiers in immunology

Published: January 16, 2025

Targeting CD276 for T cell-based immunotherapy of breast cancer.

Targeting CD276 for T cell-based immunotherapy of breast cancer.

Journal: Journal of translational medicine

Published: June 14, 2024

Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.

Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.

Journal: Science translational medicine

Published: March 06, 2024

PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.

PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.

Journal: Journal for immunotherapy of cancer

Published: December 21, 2023

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.

Journal: Nature communications

Published: June 14, 2023

An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.

An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: October 06, 2022

DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts.

DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts.

Journal: Nature communications

Published: October 04, 2022

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies.

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies.

Journal: Journal for immunotherapy of cancer

Published: December 13, 2021

Partial p53 reactivation is sufficient to induce cancer regression.

Partial p53 reactivation is sufficient to induce cancer regression.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 15, 2021

p53 partial loss-of-function mutations sensitize to chemotherapy.

p53 partial loss-of-function mutations sensitize to chemotherapy.

Journal: Oncogene

Published: June 09, 2021

DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis.

DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis.

Journal: Scientific reports

Published: June 04, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026